Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
-- Successful Phase II ‘CLEAR’ Clinical Trial Demonstrated Rapid Onset of Benefit While Eliminating Need for Chronic High-Dose Steroids in ANCA-Associated Vasculitis (AAV) With Complement Inhibitor...
-
ChemoCentryx to Hold Fourth Quarter 2015 Financial Results Conference Call on Monday, March 14, 2016
MOUNTAIN VIEW, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat...
-
MOUNTAIN VIEW, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat...
-
MOUNTAIN VIEW, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat...
-
-- Primary endpoint achieved: CCX168 demonstrates numerical superiority and achieves statistical significance in test for non-inferiority in BVAS response relative to standard of care -- --...
-
MOUNTAIN VIEW, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune...
-
-- All patients complete dosing in complement inhibitor CCX168 program for ANCA Associated Vasculitis; Phase II CLEAR clinical trial top-line results anticipated in December or early January -- --...
-
Phase II diabetic nephropathy trial results showing improvements in proteinuria over 52 weeks of treatment, sustained effect in follow-up period after drug withdrawal; potential renoprotective,...
-
-- In pancreatic cancer patient trial, excellent receptor blockade achieved with chemokine receptor CCR2 inhibitor CCX872, bodes well for ongoing multi-dose part of clinical trial; Patient...
-
MOUNTAIN VIEW, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI),a clinical-stage biopharmaceutical developing orally-administered therapeutics to treat autoimmune diseases,...